Drug Type AAV based gene therapy |
Synonyms |
Target |
Mechanism MOCS1 modulators(molybdenum cofactor synthesis 1 modulators), Gene expression stimulants, Gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Molybdenum Cofactor Deficiency, Complementation Group A | Preclinical | US | 07 May 2024 |